• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Transphorm Announces Fiscal 2023 Third Quarter Financial Results and Provides Business Update

    2/22/23 8:00:00 AM ET
    $TGAN
    Semiconductors
    Technology
    Get the next $TGAN alert in real time by email

    Product Revenue up 25% from Fiscal 2023 Q2

    Company to Host Webcast February 23rd at 11:00 a.m. ET

    Transphorm, Inc. (NASDAQ:TGAN)—a pioneer in and global supplier of high-reliability, high-performance gallium nitride (GaN) power conversion products, announced today financial results for its 2023 fiscal third quarter ended December 31, 2022.

    Fiscal 2023 Third Quarter and Recent Highlights

    (All comparisons are to the third quarter of fiscal 2022, unless otherwise noted.)

    • Revenue of $4.5 million, compared to revenue of $3.7 million in the prior quarter, and $4.6 million in fiscal 2022. Product revenue was up 25% on a sequential basis and 9% compared to the same period in fiscal 2022.
    • Increased total design-ins for power adapters and fast chargers to over 80 (with over 25 in production) and total design-ins for higher power (300 Watt – 4 Kilowatt) to over 55 (with over 25 in production).
    • Robust 5-year pipeline opportunity now stands at over $400 million.
    • Shipping production quantities of Transphorm SuperGaN Technology used in HPi ("HP") power adapter (as revealed by a recent product teardown), solidifying the company's GaN-FET technology in the low and mid-power adapter space.
    • Secured and shipped a new production order for 100 thousand units for another world-wide top 5 laptop manufacturer.
    • New >2 kW UPS production win with a global leader in energy, continuing Transphorm leadership in high-power GaN.
    • The Company's products have exceeded 100 billion hours of field operating reliability including in both low-power and high-power applications. We believe this is one of the industry's best and only reported broad power spectrum reliability rating for GaN power.
    • Announced the availability of a new 240W Power Adapter Reference Design, which brings industry-standard Thru-Hole Packaging delivering power density advantages at low cost to power supplies.
    • Completed submission for a $15 million Navy program, which, if awarded, will expand MOCVD manufacturing capacity and capability to increase the Company's RF Epiwafer sales (TGAN's 2nd business vertical).

    Transphorm President, COO, and Co-founder, Primit Parikh, commented, "We grew revenue 22% sequentially and remain well-positioned to achieve our long-term operating goals. Our business momentum is exemplified by another strong quarter of design wins as we aggressively pursued and won numerous additional designs in both high-power and low-power markets, including world-wide tier-1 leaders like HP, which represents a significant milestone and the culmination of our intense dedication to quality and reliability, with ease of use and top performance. We look forward to building on our success in this segment of the adapter market, while further growing our leadership in high-power which comprised more than 70% of our revenue in the quarter."

    Dr. Parikh added, "While we still face near term macro-headwinds, we remain well-positioned to translate the above momentum to business growth in fiscal 2024. We also made solid progress on our plans to ramp up additional capacity over the coming year, in order to be prepared and ready to meet the significant demand that lies ahead."

    "This quarter saw solid execution and higher than expected revenues, with our product revenues being driven by strong traction in the Higher Power space. As we enter calendar year 2023, the Company is well positioned and remains keenly focused on achieving continued short-term momentum and long-term growth, driven by a robust pipeline," stated Cameron McAulay, Chief Financial Officer.

    Fiscal 2023 Third Quarter Financial Results

    Revenue for the third quarter of fiscal 2023 was $4.5 million, compared to $3.7 million in the prior quarter and $4.6 million for the third quarter of fiscal 2022. Product revenue reflected yet another strong quarter from ramping shipments of GaN products for a broad range of power conversion applications, with a 25% increase over the prior quarter and a 9% increase from the third quarter of fiscal 2022.

    Operating expenses on a GAAP basis were $7.2 million in the third quarter of fiscal 2023, compared to $5.9 million in the prior quarter and $5.4 million in the third quarter of fiscal 2022. Third quarter of fiscal 2023 operating expenses consisted of R&D expenses of $2.3 million and SG&A expenses of $4.9 million. On a non-GAAP basis, operating expenses in the third quarter of fiscal 2023 were $5.9 million, compared with non-GAAP operating expenses of $5.1 million in the prior quarter and $4.4 million in the third quarter of fiscal 2022.

    GAAP net loss for the third quarter of fiscal 2023 was ($10.5) million, or ($0.18) per share, compared to GAAP net loss of ($6.0) million, or ($0.10) per share, in the prior quarter, and GAAP net loss of ($4.2) million, or ($0.08) per share, in the third quarter of fiscal 2022. On a non-GAAP basis, net loss for the third quarter of fiscal 2023 was ($9.1) million, or ($0.16) per share, compared to non-GAAP net loss of ($5.1) million, or ($0.09) per share, in the prior quarter, and non-GAAP net loss of ($4.3) million, or ($0.09) per share, in the third quarter of fiscal 2022. These numbers for the third quarter included a one time write-off of $2.8 million, or ($0.05) per share for epiwafer inventory largely resulting from the process of bringing up our Japan epi reactors over the last several quarters.

    Cash, cash equivalents and restricted cash as of December 31, 2022, were $23.6 million.

    Conference Call and Webcast Information

    Event:

    Transphorm Fiscal 2023 Third Quarter Financial Results

    Date:

    Thursday, February 23, 2023

    Time:

    11:00 a.m. Eastern Time

    Registration:

    https://register.vevent.com/register/BI851a7746d2294d99978db9598035906d

    Investors and analysts will receive a unique dial-in number and PIN number, once registered.

    A replay and the supporting presentation materials will be available on the day of the conference call and for approximately 90 days on the Investor Relations section of the Company's website. Additionally, an audio replay of the conference call will be available after the conclusion of the call and through March 2, 2023.

    About Transphorm

    Transphorm, Inc., a global leader in the GaN revolution, designs and manufactures high performance and high reliability GaN semiconductors for high voltage power conversion applications. Having one of the largest Power GaN IP portfolios of more than 1,000 owned or licensed patents, Transphorm produces the industry's first JEDEC and AEC-Q101 qualified high voltage GaN semiconductor devices. The Company's vertically integrated device business model allows for innovation at every development stage: design, fabrication, device, and application support. Transphorm's innovations are moving power electronics beyond the limitations of silicon to achieve over 99% efficiency, 40% more power density and 20% lower system cost. Transphorm is headquartered in Goleta, California and has manufacturing operations in Goleta and Aizu, Japan. For more information, please visit www.transphormusa.com. Follow us on Twitter @transphormusa and WeChat @ Transphorm GaN.

    Non-GAAP Financial Measures

    This press release includes and makes reference to certain non-GAAP financial measures. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.

    Transphorm believes that the presentation of non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. Transphorm believes that these non-GAAP financial measures provide additional insight into Transphorm's ongoing performance and core operational activities and has chosen to provide these measures for more consistent and meaningful comparison between periods. These measures should only be used to evaluate Transphorm's results of operations in conjunction with the corresponding GAAP measures. The non-GAAP results exclude the effect of stock-based compensation, depreciation, amortization, change in fair value of promissory note and other income in joint venture.

    A reconciliation between GAAP and non-GAAP financial results is provided in the financial statements portion of this press release.

    Forward-Looking Statements

    This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company's positioning to achieve long-term operating goals, the Company's ability to expand its manufacturing capacity and meet anticipated demand, industry acceptance of GaN technology, and the Company's pipeline and future anticipated growth. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: risks related to Transphorm's operations, such as additional financing requirements and access to capital; competition; the ability of Transphorm to protect its intellectual property rights; and other risks set forth in the Company's filings with the Securities and Exchange Commission. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

     

    Transphorm, Inc.

    Condensed Consolidated Balance Sheets

    (in thousands)

     

     

    December 31, 2022

    (unaudited)

     

    March 31, 2022

    (audited)

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    23,149

     

     

    $

    33,435

     

    Restricted cash

     

    500

     

     

     

    500

     

    Accounts receivable

     

    3,704

     

     

     

    2,558

     

    Inventory

     

    7,476

     

     

     

    6,330

     

    Prepaid expenses and other current assets

     

    1,570

     

     

     

    1,971

     

    Total current assets

     

    36,399

     

     

     

    44,794

     

    Property and equipment, net

     

    5,367

     

     

     

    1,649

     

    Operating lease right-of-use assets

     

    3,173

     

     

     

    —

     

    Goodwill

     

    1,097

     

     

     

    1,180

     

    Intangible assets, net

     

    395

     

     

     

    617

     

    Investment in joint venture

     

    647

     

     

     

    143

     

    Other assets

     

    2,167

     

     

     

    263

     

    Total assets

    $

    49,245

     

     

    $

    48,646

     

     

     

     

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable and accrued expenses

    $

    4,016

     

     

    $

    3,588

     

    Deferred revenue

     

    —

     

     

     

    346

     

    Accrued interest

     

    184

     

     

     

    180

     

    Accrued payroll and benefits

     

    1,657

     

     

     

    1,171

     

    Operating lease liabilities

     

    536

     

     

     

    —

     

    Revolving credit facility

     

    12,000

     

     

     

    —

     

    Total current liabilities

     

    18,393

     

     

     

    5,285

     

    Revolving credit facility, net of current portion

     

    —

     

     

     

    12,000

     

    Operating lease liabilities, net of current portion

     

    2,670

     

     

     

    —

     

    Total liabilities

     

    21,063

     

     

     

    17,285

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Common stock

     

    6

     

     

     

    5

     

    Additional paid-in capital

     

    229,954

     

     

     

    211,190

     

    Accumulated deficit

     

    (200,446

    )

     

     

    (178,638

    )

    Accumulated other comprehensive loss

     

    (1,332

    )

     

     

    (1,196

    )

    Total Stockholders' equity

     

    28,182

     

     

     

    31,361

     

    Total liabilities and stockholders' equity

    $

    49,245

     

     

    $

    48,646

     

    Transphorm, Inc.

    Condensed Consolidated Statements of Operations (unaudited)

    (in thousands except share and per share data)

     

     

    Three Months Ended

     

    Nine Months Ended

     

    December 31, 2022

     

    September 30, 2022

     

    December 31, 2021

     

    December 31, 2022

     

    December 31, 2021

    Revenue, net

    $

    4,493

     

     

    $

    3,670

     

     

    $

    4,604

     

     

    $

    13,319

     

     

    $

    19,123

     

    Cost of goods sold

     

    7,162

     

     

     

    3,232

     

     

     

    3,935

     

     

     

    14,444

     

     

     

    8,741

     

    Gross (loss) profit

     

    (2,669

    )

     

     

    438

     

     

     

    669

     

     

     

    (1,125

    )

     

     

    10,382

     

    Operating expenses:

     

     

     

     

     

     

     

     

     

    Research and development

     

    2,325

     

     

     

    1,830

     

     

     

    1,609

     

     

     

    5,895

     

     

     

    5,023

     

    Sales and marketing

     

    1,447

     

     

     

    1,066

     

     

     

    976

     

     

     

    3,596

     

     

     

    2,488

     

    General and administrative

     

    3,457

     

     

     

    3,044

     

     

     

    2,852

     

     

     

    9,818

     

     

     

    8,309

     

    Total operating expenses

     

    7,229

     

     

     

    5,940

     

     

     

    5,437

     

     

     

    19,309

     

     

     

    15,820

     

    Loss from operations

     

    (9,898

    )

     

     

    (5,502

    )

     

     

    (4,768

    )

     

     

    (20,434

    )

     

     

    (5,438

    )

    Interest expense

     

    184

     

     

     

    184

     

     

     

    187

     

     

     

    550

     

     

     

    611

     

    Loss in joint venture

     

    799

     

     

     

    684

     

     

     

    712

     

     

     

    2,065

     

     

     

    3,294

     

    Changes in fair value of promissory note

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (605

    )

    Other income, net

     

    (421

    )

     

     

    (375

    )

     

     

    (1,503

    )

     

     

    (1,241

    )

     

     

    (3,502

    )

    Loss before tax expense

     

    (10,460

    )

     

     

    (5,995

    )

     

     

    (4,164

    )

     

     

    (21,808

    )

     

     

    (5,236

    )

    Tax expense

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Net loss

    $

    (10,460

    )

     

    $

    (5,995

    )

     

    $

    (4,164

    )

     

    $

    (21,808

    )

     

    $

    (5,236

    )

    Net loss per share - basic and diluted

    $

    (0.18

    )

     

    $

    (0.10

    )

     

    $

    (0.08

    )

     

    $

    (0.38

    )

     

    $

    (0.12

    )

    Weighted average common shares outstanding - basic and diluted

     

    56,739,450

     

     

     

    56,619,662

     

     

     

    49,147,630

     

     

     

    55,926,828

     

     

     

    43,671,321

     

     

    Transphorm, Inc.

    Reconciliation of GAAP and Non-GAAP Financial Information (unaudited)

    (in thousands except share and per share data)

     

     

    Three Months Ended

     

    Nine Months Ended

     

    December 31, 2022

     

    September 30, 2022

     

    December 31, 2021

     

    December 31, 2022

     

    December 31, 2021

    GAAP net loss

    $

    (10,460

    )

     

    $

    (5,995

    )

     

    $

    (4,164

    )

     

    $

    (21,808

    )

     

    $

    (5,236

    )

    Adjustments:

     

     

     

     

     

     

     

     

     

    Stock-based compensation

     

    1,123

     

     

     

    636

     

     

     

    848

     

     

     

    2,341

     

     

     

    1,856

     

    Depreciation

     

    180

     

     

     

    165

     

     

     

    142

     

     

     

    497

     

     

     

    399

     

    Amortization

     

    74

     

     

     

    74

     

     

     

    74

     

     

     

    222

     

     

     

    222

     

    Changes in fair value of promissory note

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (605

    )

    Other income

     

    —

     

     

     

    —

     

     

     

    (1,222

    )

     

     

    —

     

     

     

    (2,677

    )

    Total adjustments to GAAP net loss

     

    1,377

     

     

     

    875

     

     

     

    (158

    )

     

     

    3,060

     

     

     

    (805

    )

    Non-GAAP net loss

    $

    (9,083

    )

     

    $

    (5,120

    )

     

    $

    (4,322

    )

     

    $

    (18,748

    )

     

    $

    (6,041

    )

    GAAP net loss per share - basic and diluted

    $

    (0.18

    )

     

    $

    (0.10

    )

     

    $

    (0.08

    )

     

    $

    (0.38

    )

     

    $

    (0.12

    )

    Adjustment

     

    0.01

     

     

     

    0.01

     

     

     

    (0.01

    )

     

     

    0.04

     

     

     

    (0.02

    )

    Non-GAAP net loss per share - basic and diluted

    $

    (0.16

    )

     

    $

    (0.09

    )

     

    $

    (0.09

    )

     

    $

    (0.33

    )

     

    $

    (0.14

    )

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended

     

    Nine Months Ended

     

    December 31, 2022

     

    September 30, 2022

     

    December 31, 2021

     

    December 31, 2022

     

    December 31, 2021

    GAAP operating expenses

    $

    7,229

     

    $

    5,940

     

    $

    5,437

     

    $

    19,309

     

    $

    15,820

    Adjustments:

     

     

     

     

     

     

     

     

     

    Stock-based compensation

     

    1,035

     

     

    583

     

     

    796

     

     

    2,161

     

     

    1,738

    Depreciation

     

    180

     

     

    165

     

     

    142

     

     

    497

     

     

    399

    Amortization

     

    74

     

     

    74

     

     

    74

     

     

    222

     

     

    222

    Total adjustments to GAAP operating expenses

     

    1,289

     

     

    822

     

     

    1,012

     

     

    2,880

     

     

    2,359

    Non-GAAP operating expenses

    $

    5,940

     

    $

    5,118

     

    $

    4,425

     

    $

    16,429

     

    $

    13,461

     

    Transphorm, Inc.

    Condensed Consolidated Statements of Cash Flows (unaudited)

    (in thousands)

     

     

    Nine Months Ended December 31,

     

     

    2022

     

     

     

    2021

     

    Cash flows from operating activities:

     

     

     

    Net loss

    $

    (21,808

    )

     

    $

    (5,236

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

    Inventory write-off

     

    2,810

     

     

     

    202

     

    Depreciation and amortization

     

    719

     

     

     

    621

     

    Amortization of right-of-use assets

     

    425

     

     

     

    —

     

    Perpetual licensing revenue from a related party

     

    —

     

     

     

    (8,000

    )

    Stock-based compensation

     

    2,342

     

     

     

    1,856

     

    Interest cost

     

    4

     

     

     

    295

     

    Gain on promissory note conversion

     

    —

     

     

     

    (1,222

    )

    Gain on sale of equipment

     

    (110

    )

     

     

    —

     

    Loss in joint venture

     

    2,065

     

     

     

    1,839

     

    Changes in fair value of derivative instruments

     

    75

     

     

     

    —

     

    Changes in fair value of promissory note

     

    —

     

     

     

    (605

    )

    Changes in operating assets and liabilities:

     

     

     

    Accounts receivable

     

    (1,221

    )

     

     

    (871

    )

    Inventory

     

    (3,956

    )

     

     

    (3,935

    )

    Prepaid expenses and other current assets

     

    401

     

     

     

    204

     

    Other assets

     

    (504

    )

     

     

    (8

    )

    Accounts payable and accrued expenses

     

    428

     

     

     

    1,359

     

    Deferred revenue

     

    (346

    )

     

     

    (238

    )

    Accrued payroll and benefits

     

    486

     

     

     

    (171

    )

    Operating lease liabilities

     

    (392

    )

     

     

    —

     

    Net cash used in operating activities

     

    (18,582

    )

     

     

    (13,910

    )

    Cash flows from investing activities:

     

     

     

    Advances and purchases of property and equipment

     

    (5,633

    )

     

     

    (690

    )

    Proceeds from sale of equipment

     

    110

     

     

     

    —

     

    Investment in joint venture

     

    (2,569

    )

     

     

    (3,765

    )

    Net cash used in investing activities

     

    (8,092

    )

     

     

    (4,455

    )

    Cash flows from financing activities:

     

     

     

    Proceeds from stock option exercise

     

    709

     

     

     

    134

     

    Proceeds from issuance of common stock

     

    16,000

     

     

     

    49,773

     

    Cost associated with issuance of common stock

     

    (280

    )

     

     

    —

     

    Payment for taxes related to net share settlement of restricted stock units

     

    (6

    )

     

     

    Net cash provided by financing activities

     

    16,423

     

     

     

    49,907

     

    Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash

     

    (35

    )

     

     

    (75

    )

    Net (decrease) increase in cash, cash equivalents and restricted cash

     

    (10,286

    )

     

     

    31,467

     

    Cash and cash equivalents and restricted cash at beginning of period

     

    33,935

     

     

     

    9,500

     

    Cash and cash equivalents at end of period

     

    23,149

     

     

     

    40,467

     

    Restricted cash at end of period

     

    500

     

     

     

    500

     

    Cash and cash equivalents and restricted cash at end of period

    $

    23,649

     

     

    $

    40,967

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005346/en/

    Get the next $TGAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TGAN

    DatePrice TargetRatingAnalyst
    6/15/2022$9.00 → $6.50Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $TGAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Transphorm downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Transphorm from Buy to Neutral and set a new price target of $6.50 from $9.00 previously

    6/15/22 7:40:43 AM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    SEC Filings

    View All

    SEC Form 15-12G filed by Transphorm Inc.

    15-12G - Transphorm, Inc. (0001715768) (Filer)

    7/1/24 9:01:49 AM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form EFFECT filed by Transphorm Inc.

    EFFECT - Transphorm, Inc. (0001715768) (Filer)

    6/21/24 12:15:13 AM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form EFFECT filed by Transphorm Inc.

    EFFECT - Transphorm, Inc. (0001715768) (Filer)

    6/21/24 12:15:04 AM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Renesas Completes Acquisition of Transphorm

    Accelerates Wide Bandgap Product Offering and Introduces 15 New GaN-Based Winning Combination Reference Designs Renesas Electronics Corporation ("Renesas" TSE:6723), a premier supplier of advanced semiconductor solutions, today announced that it has completed the acquisition of Transphorm, Inc. (NASDAQ:TGAN), a global leader in gallium nitride (GaN) power semiconductors, as of June 20, 2024. With the closing of the acquisition now completed, Renesas will immediately start offering GaN-based power products and related reference designs to meet the rising demand for wide bandgap (WBG) semiconductor products. This press release features multimedia. View the full release here: https://www.bu

    6/20/24 8:30:00 AM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Demonstrates a Bidirectional SuperGaN Power Supply with New Reference Design for E-Mobility and Energy/Industrial Markets

    300 W DC-to-DC Battery Charger Board Showcases Key Capability of GaN Technology Necessary to Advance E-Mobility Applications Transphorm, Inc. (NASDAQ:TGAN), the global leader in robust GaN power semiconductors, today announced the release of a new 300 W DC-to-DC GaN reference design for 2- and 3-wheeled electric vehicle battery chargers. The TDDCDC-TPH-IN-BI-LLC-300W-RD design uses TP65H150G4PS 150 mOhm SuperGaN® FETs in a robust TO-220 package to power a high performing, high efficiency energy harvesting and distribution battery charging system. The new board notably demonstrates one of the most anticipated value propositions of a GaN power supply: bidirectionality. This capability indic

    6/11/24 3:00:00 AM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm's SuperGaN at PCIM 2024: Surpassing SiC and e-mode GaN Capabilities in High Power Systems

    Lower Losses, Higher Performance Delivered by Transphorm's Normally-off d-mode Platform Enables Electric Vehicle, Datacenter/AI, and Other Multi-market Power Systems, Along with Groundbreaking GaN Product Innovations Transphorm, Inc. (NASDAQ:TGAN), the global leader in robust GaN power semiconductors, announced today that its PCIM 2024 showcase will underscore its ability to outperform competitive wide bandgap technologies in higher power systems. For example, Transphorm's normally-off d-mode SuperGaN® platform delivers higher electron mobility resulting in lower crossover losses versus Silicon Carbide—making it more a cost-effective, higher performing solution for various electric vehicl

    5/20/24 8:30:00 AM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Kkr Phorm Investors L.P. sold $124,501,037 worth of shares (24,411,968 units at $5.10) (SEC Form 4)

    4 - Transphorm, Inc. (0001715768) (Issuer)

    6/20/24 4:30:24 PM ET
    $TGAN
    Semiconductors
    Technology

    PRESIDENT AND CEO Parikh Primit returned 489,310 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Transphorm, Inc. (0001715768) (Issuer)

    6/20/24 4:05:22 PM ET
    $TGAN
    Semiconductors
    Technology

    Chief Financial Officer Mcaulay Cameron returned 182,048 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Transphorm, Inc. (0001715768) (Issuer)

    6/20/24 4:05:17 PM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Transphorm Inc.

    SC 13D/A - Transphorm, Inc. (0001715768) (Subject)

    6/20/24 4:30:51 PM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form SC 13G/A filed by Transphorm Inc. (Amendment)

    SC 13G/A - Transphorm, Inc. (0001715768) (Subject)

    2/14/24 10:15:50 AM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form SC 13G/A filed by Transphorm Inc. (Amendment)

    SC 13G/A - Transphorm, Inc. (0001715768) (Subject)

    2/13/24 1:41:50 PM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Financials

    Live finance-specific insights

    View All

    Renesas Completes Acquisition of Transphorm

    Accelerates Wide Bandgap Product Offering and Introduces 15 New GaN-Based Winning Combination Reference Designs Renesas Electronics Corporation ("Renesas" TSE:6723), a premier supplier of advanced semiconductor solutions, today announced that it has completed the acquisition of Transphorm, Inc. (NASDAQ:TGAN), a global leader in gallium nitride (GaN) power semiconductors, as of June 20, 2024. With the closing of the acquisition now completed, Renesas will immediately start offering GaN-based power products and related reference designs to meet the rising demand for wide bandgap (WBG) semiconductor products. This press release features multimedia. View the full release here: https://www.bu

    6/20/24 8:30:00 AM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Announces Fiscal 2024 Third Quarter Results and Provides Business Update

    Transphorm, Inc. (NASDAQ:TGAN)—a global leader in GaN, the future of next generation power systems, announced today its financial results for the third quarter of its fiscal year ending March 31, 2024 ("Q3 Fiscal 2024"). On January 10, 2024, Transphorm announced that it entered into a definitive agreement to be acquired by a subsidiary of Renesas Electronics Corporation. The transaction values Transphorm at approximately $339 million. Key Business Highlights Reported total revenue of $4.7 million for Q3 Fiscal 2024, an increase of 4.0% over the same quarter last year and a decrease of 6.8% from the prior quarter. Product revenue was $3.2 million in the quarter, a decrease of 20%

    2/20/24 4:05:00 PM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Announces Fiscal 2024 Second Quarter Results and Provides Business Update

    - Reports Second Quarter Year-Over-Year Revenue Grew 37% to $5.0 Million as Gross Margin Increased by 11.5% to 23% - Product Revenue Increased to $3.55 Million, Up 18% Over the Prior Quarter - Recently Engaged BofA Securities, Inc. to Act as Financial Advisor in Company's Strategic Review to Enhance Stockholder Value - Company to Host Webcast Today at 5:00 p.m. EST to Review Quarterly Results and Provide a Business Update Transphorm, Inc. (NASDAQ:TGAN)—a global leader in GaN, the future of next generation power systems, announced today its financial results for the second quarter of its fiscal year ending March 31, 2024 ("Q2 Fiscal 2024"). Primit Parikh, Transphorm's CEO and Co-Fo

    11/9/23 4:05:00 PM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Leadership Updates

    Live Leadership Updates

    View All

    Transphorm Announces Appointment of Company Co-founders as Chief Executive Officer and Board Chair

    Follows Retirement of CEO and as part of the Company's Planned Succession Strategy Transphorm, Inc. (NASDAQ:TGAN)—a pioneer in and global supplier of high-reliability, high-performance gallium nitride (GaN) power conversion products, announced that its Board of Directors has appointed Dr. Primit Parikh as President and Chief Executive Officer of the Company and as a member of the Board. The Board also appointed Dr. Umesh Mishra to serve as Chair of the Board. Both of these appointments are effective May 15, 2023. Dr. Parikh and Dr. Mishra, who co-founded the Company's main operating subsidiary Transphorm Technology Inc., succeed Mario Rivas, who has served as the Company's Chief Executi

    5/15/23 8:30:00 AM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Appoints Six Company Leaders

    Company Veterans and Industry Leaders to Drive Next Phase of Growth Transphorm, Inc. (NASDAQ:TGAN)—a pioneer in and a global supplier of high reliability, high performance gallium nitride (GaN) power conversion products—announced today the appointment of six company leaders. The roles are being filled by company veterans as well as newly hired experts, strategically building out Transphorm's executive bench. The collective sales, operations, engineering, and product marketing skillsets brought by these individuals will contribute to Transphorm's business growth and customer support strategies as the company responds to a rapidly rising demand for high voltage GaN power semiconductors acros

    10/27/22 9:00:00 AM ET
    $TGAN
    Semiconductors
    Technology